FDA Accepts IND Application for Edge Therapeutics' EG-1962 (nimodipine microparticles)

Published: Jun 10, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW PROVIDENCE, N.J.--(BUSINESS WIRE)--Edge Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing life-saving hospital products for acute, fatal or debilitating conditions, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's Investigational New Drug (IND) application for EG-1962, a novel bio-absorbable nimodipine microparticle formulation. Edge is developing EG-1962 for the prevention of delayed cerebral ischemia (DCI), a life-threatening complication of subarachnoid hemorrhage (SAH). The application was accepted within 30 days of submission to the FDA.

Help employers find you! Check out all the jobs and post your resume.

Back to news